

**Brilliant Violet 605™ anti-human CD200 (OX2)**

**Catalog # / Size:** 2246085 / 25 tests  
2246090 / 100 tests

**Clone:** OX-104

**Isotype:** Mouse IgG1,  $\kappa$


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** VII 70655

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD200 (clone OX-104) Brilliant Violet 605™ (filled histogram) or mouse IgG1,  $\kappa$  Brilliant Violet 605™ isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is  $\leq 5$  microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemistry of formalin-fixed paraffin-embedded sections<sup>1</sup> and acetone-fixed frozen sections<sup>2</sup>, and blocking of CD200 interaction with CD200R.

**Application References:** 1. Patel GK, *et al.* 2012. *J. Invest. Dermatol.* 132:401. (IHC)  
2. Wright GJ, *et al.* 2001. *Immunology* 102:173. (IHC)  
2. Foster-Cuevas M, *et al.* 2004. *J. Virol.* 78:7667. (FC)

**Description:** CD200, also known as OX2, is a member of the immunoglobulin superfamily

(IgSF). It is a monomorphic cell surface glycoprotein that is expressed on thymocytes, neurons, endothelium, follicular dendritic cells in all lymphoid organs, a subset of CD34<sup>+</sup> progenitor cells, and at low levels on some smooth muscle and B lymphocytes. It is not expressed on NK cells, monocytes, granulocytes, or platelets. CD200 costimulates T cell proliferation. It may regulate myeloid cell activity in a variety of tissues. The interaction between CD200 (OX2) and CD200 receptor (OX2R) system is of importance in the control of macrophage and granulocyte activation, which may contribute to pathways that suppress and limit macrophage induced inflammatory damage in tissue.

**Antigen**  
**References:**

1. Wright GJ, *et al.* 2001. *Immunol.* 102:173.
2. Foster-Cuevas M, *et al.* 2004. *J. Virol.* 78:7667.
3. Mason D, *et al.* 2002. ed. Leukocyte Typing VII. New York:Oxford Univ. Press.
4. Broderick C,